Tag: pruritus therapeutics market trends

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Pruritus Therapeutics Market Expected To Grow In Terms Of Size?

In recent times, there has been a consistent increase in the market size of pruritus therapeutics. From $11.89 billion in 2024, it is set to expand to $12.38 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 4.1%. The historical period’s development can be related to an increase in pruritus cases, varied reasons and conditions, an escalating elderly population, and a focus on bettering patient life quality.

There is an anticipated strong surge in the pruritus therapeutics market over the next couple of years. The market is projected to expand to “$15.7 billion by 2029 with an impressive compound annual growth rate (CAGR) of 6.1%. This anticipated growth in the prognosis period can be linked to an improved understanding of pruritus pathophysiology, advancements in drug formulations and delivery, a shift toward personalized medicine, an escalation in dermatological R&D, enhanced awareness and diagnosis rates, and escalating interest in plant-based and herbal solutions. Key trends during the prognosis period will include the creation of itch-specific receptor agonists and antagonists, the increased market focus on personalized therapeutic strategies, the merging of technology in itch tracking and treatment, and partnerships for interdisciplinary research.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

Which Industry Forces Are Driving The Pruritus Therapeutics Market Forward?

An increase in the prevalence of skin-related disorders is projected to boost the pruritus therapeutics market’s expansion. Dermatological issues cover a spectrum from acne and eczema to skin cancer and fungal infections and can include conditions relating to skin, hair, nails, and mucous membranes. The specific cause of the itchiness frequently dictates the application of pruritus treatments for these skin diseases. Treatments include topical applications, emollients and moisturizers, medications that suppress the immune system, and medicines specifically for itching. For example, the American Cancer Society, a non-profit organization based in the US committed to eradicating cancer, anticipated 108,270 skin cancer cases in January 2024, a 3.2% rise from the 104,930 instances recorded in 2023. So, the escalating incidence of skin disorders is fuelling the pruritus therapeutics market’s growth.

What Is The Segment Breakdown Of The Pruritus Therapeutics Market?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

How Are Global Trends Impacting The Development Of The Pruritus Therapeutics Market?

Leading firms in the pruritus therapeutics market are concentrating on the creation of targeted remedies for specific patient groups and rare conditions, such as a non-systemic ileal bile acid transport inhibitor. This personal approach to medicine aims to fill gaps in currently available treatments. This specific type of drug targets the absorption of bile acid in the gut without major impacts on the body’s systemic circulation, thus reducing potential side effects. For instance, in June 2023, Ipsen, a pharmaceutical company from France, was granted approval from the Food and Drug Administration (FDA), an agency of the US Department of Health and Human Services, for the use of Bylvay (odevixibat) to treat cholestatic pruritus in Alagille syndrome (ALGS) patients who are at least 12 months old. Bylvay, an IBATi taken once daily, demonstrates very little systemic exposure and is the first FDA approved treatment for cholestatic pruritus related to progressive familial intrahepatic cholestasis (PFIC) in the United States. The drug had already been approved for PFIC treatment in Europe and is now available by prescription for eligible ALGS patients in the US.

Which Firms Are Driving Innovation Within The Pruritus Therapeutics Market?

Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Pruritus Therapeutics Market?

North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Pruritus Therapeutics Market Heading Into 2029?

The market size for pruritus therapeutics has seen a consistent rise in recent years. The market is projected to expand from $11.89 billion in 2024 to $12.38 billion in 2025, with a compound annual growth rate (CAGR) of 4.1%. Factors such as an increase in pruritus cases, a range of causative factors and conditions, a growing elderly population, and a focus on improving the patient’s quality of life have contributed to the growth during the historic period.

In the coming years, the pruritus therapeutics market size is anticipated to witness solid growth. The market is projected to reach “$15.7 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period is due to a broader understanding of pruritus pathophysiology, advancements in drug formulations and delivery, a focus on tailor-made medicine, growth in dermatological R&D, increasing consciousness and diagnosis rates, and escalating interest in plant-based and herbal remedies. Noteworthy trends for the forecast period comprise the creation of itch-specific receptor agonists and antagonists, market concentration on individual therapeutic strategies, the amalgamation of technology in itch monitoring and management, and partnerships for interdisciplinary research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

Which Factors Are Pushing The Pruritus Therapeutics Market Forward?

The pruritus therapeutics market is projected to grow due to an increase in dermatological disorders. These disorders encompass a range of conditions affecting the skin, hair, nail, and mucous membrane, including skin cancer, fungal infections, acne, and eczema. The specific cause of the itch often dictates the type of pruritus treatment used for skin diseases. Treatments may involve topical applications, emollients and moisturizers, medications to suppress the immune system, or drugs to relieve itching. The American Cancer Society, a non-profit organization in the US focused on eradicating cancer, predicted 108,270 cases of skin cancer in January 2024. This marks a 3.2% rise from the 104,930 cases reported in 2023. Consequently, the increasing prevalence of skin disorders is stimulating the growth of the pruritus therapeutics market.

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Which Trends Are Redefining The Future Landscape Of The Pruritus Therapeutics Industry?

A key trend in the pruritus therapeutics market is the move by major corporations to develop specifically targeted treatments for unique diseases and specific patient groups. An example of this is the focus on non-systemic ileal bile acid transport inhibitor therapies, which can provide personalized care for previously unaddressed medical needs. This type of medication aims to interfere with bile acid absorption in the gut without significantly impacting the overall circulation of the body, thus reducing potential side effects. In June 2023, a noteworthy example was Ipsen, a pharmaceutical company in France. They obtained approval from the Food and Drug Administration (FDA), a federal agency under the US Department of Health and Human Services, for Bylvay (odevixibat). This drug is used to treat cholestatic pruritus in Alagille syndrome (ALGS) patients ages 12 months and older. Being a non-systemic ileal bile acid transport inhibitor (IBATi) administered once daily, Bylvay only has minor systemic exposure and is currently the first approved therapy for cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC) within the U.S. Prior to this approval, Bylvay was only authorized for treating PFIC in Europe, but can now be prescribed to eligible ALGS patients.

Which Organizations Are Driving Progress In The Pruritus Therapeutics Industry?

Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Pruritus Therapeutics Industry?

North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Pruritus Therapeutics Market Heading Into 2029?

The market size for pruritus therapeutics has seen a consistent rise in recent years. The market is projected to expand from $11.89 billion in 2024 to $12.38 billion in 2025, with a compound annual growth rate (CAGR) of 4.1%. Factors such as an increase in pruritus cases, a range of causative factors and conditions, a growing elderly population, and a focus on improving the patient’s quality of life have contributed to the growth during the historic period.

In the coming years, the pruritus therapeutics market size is anticipated to witness solid growth. The market is projected to reach “$15.7 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period is due to a broader understanding of pruritus pathophysiology, advancements in drug formulations and delivery, a focus on tailor-made medicine, growth in dermatological R&D, increasing consciousness and diagnosis rates, and escalating interest in plant-based and herbal remedies. Noteworthy trends for the forecast period comprise the creation of itch-specific receptor agonists and antagonists, market concentration on individual therapeutic strategies, the amalgamation of technology in itch monitoring and management, and partnerships for interdisciplinary research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

Which Factors Are Pushing The Pruritus Therapeutics Market Forward?

The pruritus therapeutics market is projected to grow due to an increase in dermatological disorders. These disorders encompass a range of conditions affecting the skin, hair, nail, and mucous membrane, including skin cancer, fungal infections, acne, and eczema. The specific cause of the itch often dictates the type of pruritus treatment used for skin diseases. Treatments may involve topical applications, emollients and moisturizers, medications to suppress the immune system, or drugs to relieve itching. The American Cancer Society, a non-profit organization in the US focused on eradicating cancer, predicted 108,270 cases of skin cancer in January 2024. This marks a 3.2% rise from the 104,930 cases reported in 2023. Consequently, the increasing prevalence of skin disorders is stimulating the growth of the pruritus therapeutics market.

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Which Trends Are Redefining The Future Landscape Of The Pruritus Therapeutics Industry?

A key trend in the pruritus therapeutics market is the move by major corporations to develop specifically targeted treatments for unique diseases and specific patient groups. An example of this is the focus on non-systemic ileal bile acid transport inhibitor therapies, which can provide personalized care for previously unaddressed medical needs. This type of medication aims to interfere with bile acid absorption in the gut without significantly impacting the overall circulation of the body, thus reducing potential side effects. In June 2023, a noteworthy example was Ipsen, a pharmaceutical company in France. They obtained approval from the Food and Drug Administration (FDA), a federal agency under the US Department of Health and Human Services, for Bylvay (odevixibat). This drug is used to treat cholestatic pruritus in Alagille syndrome (ALGS) patients ages 12 months and older. Being a non-systemic ileal bile acid transport inhibitor (IBATi) administered once daily, Bylvay only has minor systemic exposure and is currently the first approved therapy for cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC) within the U.S. Prior to this approval, Bylvay was only authorized for treating PFIC in Europe, but can now be prescribed to eligible ALGS patients.

Which Organizations Are Driving Progress In The Pruritus Therapeutics Industry?

Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Pruritus Therapeutics Industry?

North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Pruritus Therapeutics Market Heading Into 2029?

The market size for pruritus therapeutics has seen a consistent rise in recent years. The market is projected to expand from $11.89 billion in 2024 to $12.38 billion in 2025, with a compound annual growth rate (CAGR) of 4.1%. Factors such as an increase in pruritus cases, a range of causative factors and conditions, a growing elderly population, and a focus on improving the patient’s quality of life have contributed to the growth during the historic period.

In the coming years, the pruritus therapeutics market size is anticipated to witness solid growth. The market is projected to reach “$15.7 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period is due to a broader understanding of pruritus pathophysiology, advancements in drug formulations and delivery, a focus on tailor-made medicine, growth in dermatological R&D, increasing consciousness and diagnosis rates, and escalating interest in plant-based and herbal remedies. Noteworthy trends for the forecast period comprise the creation of itch-specific receptor agonists and antagonists, market concentration on individual therapeutic strategies, the amalgamation of technology in itch monitoring and management, and partnerships for interdisciplinary research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

Which Factors Are Pushing The Pruritus Therapeutics Market Forward?

The pruritus therapeutics market is projected to grow due to an increase in dermatological disorders. These disorders encompass a range of conditions affecting the skin, hair, nail, and mucous membrane, including skin cancer, fungal infections, acne, and eczema. The specific cause of the itch often dictates the type of pruritus treatment used for skin diseases. Treatments may involve topical applications, emollients and moisturizers, medications to suppress the immune system, or drugs to relieve itching. The American Cancer Society, a non-profit organization in the US focused on eradicating cancer, predicted 108,270 cases of skin cancer in January 2024. This marks a 3.2% rise from the 104,930 cases reported in 2023. Consequently, the increasing prevalence of skin disorders is stimulating the growth of the pruritus therapeutics market.

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Which Trends Are Redefining The Future Landscape Of The Pruritus Therapeutics Industry?

A key trend in the pruritus therapeutics market is the move by major corporations to develop specifically targeted treatments for unique diseases and specific patient groups. An example of this is the focus on non-systemic ileal bile acid transport inhibitor therapies, which can provide personalized care for previously unaddressed medical needs. This type of medication aims to interfere with bile acid absorption in the gut without significantly impacting the overall circulation of the body, thus reducing potential side effects. In June 2023, a noteworthy example was Ipsen, a pharmaceutical company in France. They obtained approval from the Food and Drug Administration (FDA), a federal agency under the US Department of Health and Human Services, for Bylvay (odevixibat). This drug is used to treat cholestatic pruritus in Alagille syndrome (ALGS) patients ages 12 months and older. Being a non-systemic ileal bile acid transport inhibitor (IBATi) administered once daily, Bylvay only has minor systemic exposure and is currently the first approved therapy for cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC) within the U.S. Prior to this approval, Bylvay was only authorized for treating PFIC in Europe, but can now be prescribed to eligible ALGS patients.

Which Organizations Are Driving Progress In The Pruritus Therapeutics Industry?

Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Pruritus Therapeutics Industry?

North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Pruritus Therapeutics Sector?

In the past few years, there has been a consistent increase in the market size of pruritus therapeutics. The market, which is forecasted to be valued at $11.89 billion in 2024, is anticipated to rise to $12.38 billion in 2025, marking a compound annual growth rate (CAGR) of 4.1%. This expansion during the historical phase is due to various factors including an uptick in pruritus cases, diverse origins and circumstances, increasing elderly populace, and emphasis on the quality of life of patients.

Significant expansion is anticipated in the pruritus therapeutics market in the coming years, with projections estimating it to reach a value of $15.7 billion by 2029, growing at a CAGR of 6.1%. This estimated growth during the forecast period can be linked to a deeper understanding of pruritus pathophysiology, advancements in drug formulations and delivery strategies, a focus on personalized medication, an upsurge in dermatological R&D, improved awareness and diagnosis rates, and a growing inclination towards botanical and herbal treatments. Predicted trends for the forecast period comprise the creation of itch-specific receptor agonists and antagonists, a market focus on personalized therapeutic strategies, the incorporation of technology in itch surveillance and treatment, and partnerships for interdisciplinary research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

What Forces Are Driving The Growth Of The Pruritus Therapeutics Market?

The escalating incidence of skin-related ailments is predicted to bolster the expansion of the pruritus therapeutics market in the future. Dermatological disorders encompass conditions affecting the skin, hair, nails, and mucous membrane, varying from acne and eczema to skin cancer and fungal infections. How pruritus treatments are used is often dictated by the root cause of the itch in dermatological diseases. Topical treatments, emollients and moisturizers, immunosuppressive drugs, and anti-itching medications are frequently employed to treat this condition. For example, the American Cancer Society, a non-profit organization committed to eradicating cancer in the US, reported in January 2024 that there would be 108,270 skin cancer cases, a 3.2% rise from the 104,930 cases reported in 2023. Consequently, the escalating prevalence of dermatological ailments is propelling the growth of the pruritus therapeutics market.

How Is The Pruritus Therapeutics Industry Segmented Across Key Parameters?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

What Notable Trends Are Shaping The Direction Of The Pruritus Therapeutics Market?

Leading corporates in the pneumococcal vaccine sector are introducing novel products in an attempt to boost their market profits. Merck & Co Inc., an American pharmaceutical company, for instance, unveiled the V116 vaccine in July 2023. The purpose of V116 is to target the eight unique serotypes of Streptococcus pneumoniae, which are predominantly accountable for pneumococcal disease in adults. Compared with other similar vaccines, V116 has demonstrated superior immunogenicity across diverse serotypes in adult cohorts, and it has also elicited positive immune responses in both those receiving the vaccine for the first time and those who were previously immunized. The V116 has been classified as a breakthrough therapy by the U.S. Food and Drug Administration (FDA) and is currently undergoing Phase 3 trials.

Which Companies Currently Dominate The Competitive Landscape In The Pruritus Therapeutics Industry?

Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Geographic Regions Are Driving Demand In The Pruritus Therapeutics Market?

North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Pruritus Therapeutics Market?

The anticipated acceleration of the pruritus therapeutics market is linked to the growing prevalence of dermatological conditions. Such conditions encompass a variety of skin, hair, nail, and mucous membrane disorders, including but not limited to acne, eczema, skin cancer, and fungal infections. Determining the root cause of pruritus is often instrumental in deciding the course of treatment for these skin diseases. Common treatment methods include topical remedies, emollients and moisturizers, immunosuppressive drugs, and antipruritic medications. As an example, in January 2024, the American Cancer Society – a non-profit U.S. organization working towards the eradication of cancer – forecasts that the reported cases of skin cancer will rise to 108,270, marking a 3.2% growth compared to the 104,930 cases reported in the previous year. Consequently, the escalating occurrence of skin-related disorders is fueling the expansion of the pruritus therapeutics market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

#How Does the ProjectedPruritus Therapeutics Market Growth Compare Over the Forecast Period?

The market size of pruritus therapeutics has seen robust expansion in the past few years. It is projected to rise from $11.89 billion in 2024 to $12.51 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.3%. The surge during the historical period is tied to the growing cases of pruritus, variety of causes and conditions, increase in the elderly population, and an emphasis on patient’s quality of life.

The market size for pruritus therapeutics is anticipated to witness robust expansion in the forthcoming years, reaching a valuation of $16.05 billion in 2026 at a compound annual growth rate of 6.4%. The key factors fuelling this growth during the projection period include a deeper understanding of pruritus pathophysiology, advancement in drug formulations and delivery systems, emphasis on individualized treatment, a surge in dermatological research and studies, escalating awareness and diagnosis rates, and a growing inclination towards plant-based and herbal cures. Upcoming trends for the said period encompass the creation of itch-specific receptor supporters and suppressants, industry focus on personalized therapeutic strategies, incorporation of technology in itch tracking and treatment, and partnerships for inter-disciplinary investigations.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11907

What Are the Most Significant Market Trends Transforming thePruritus Therapeutics Market?

Leading enterprises in the pruritus therapeutics market are concentrating their efforts on generating specialized treatments for rare diseases and specific patient groups, such as those requiring a non-systemic ileal bile acid transport inhibitor. This medication type is designed to address bile acid absorption in the intestine, without significantly disturbing the systemic circulation, which helps to reduce potential side effects. For example, the French pharmaceutical company Ipsen acquired approval from the Food and Drug Administration (FDA), a US-based federal agency affiliated with the Department of Health and Human Services, in June 2023 for the use of Bylvay (odevixibat). This drug is intended to treat cholestatic pruritus in Alagille syndrome (ALGS) patients who are aged 12 months and above. Bylvay, an IBATi, is delivered once a day and poses minimal systemic exposure. It represents the first drug approved for cholestatic pruritus related to progressive familial intrahepatic cholestasis (PFIC) in the United States, after previously receiving approval for PFIC treatment in Europe. The drug is now accessible for prescription use for eligible ALGS patients.

What Are the Top Market Players Propelling the Growth of thePruritus Therapeutics Industry?

Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Primary Segments of the Pruritus Therapeutics Market Are Driving Growth and Industry Transformations?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Pruritus Therapeutics Market?# Market?

North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Gobal Pruritus Therapeutics Maret 2025, By The Business Research Company:

Point-of-Care Diagnostics Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Point-of-Care Diagnostics Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Acute Myeloid Leukemia Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: